Endo International PLC (ENDP) Bond Prices Rise 2.3% Analyst
An issue of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) bonds rose 2.3% against their face value during trading on Friday after BMO Capital Markets lowered their price target on the stock from $11.00 to $10.00. The debt issue has a 6% coupon and will mature on July 15, 2023. The debt is now trading at $74.50 and was trading at $77.87 one week ago. Price moves in a company’s bonds in credit markets sometimes predict parallel moves in its stock price.
ENDP has been the subject of a number of other research reports. Royal Bank of Canada restated a “sector perform” rating and set a $9.00 price objective (down previously from $15.00) on shares of Endo International PLC in a research report on Wednesday, August 9th. Morgan Stanley cut their price objective on shares of Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating for the company in a research report on Thursday, August 10th. Deutsche Bank AG set a $13.00 price objective on shares of Endo International PLC and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research downgraded shares of Endo International PLC from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. Finally, Citigroup Inc. cut their price objective on shares of Endo International PLC from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Friday. Four equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $11.67.
In other news, CEO Paul Campanelli purchased 6,500 shares of the firm’s stock in a transaction on Monday, August 14th. The shares were bought at an average cost of $7.71 per share, with a total value of $50,115.00. Following the purchase, the chief executive officer now directly owns 213,620 shares of the company’s stock, valued at $1,647,010.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired a total of 16,000 shares of company stock worth $125,460 over the last ninety days. 0.50% of the stock is owned by corporate insiders.
Several institutional investors have recently added to or reduced their stakes in ENDP. Diamond Hill Capital Management Inc. acquired a new stake in shares of Endo International PLC during the 2nd quarter worth about $5,454,000. Canada Pension Plan Investment Board boosted its stake in shares of Endo International PLC by 93.4% during the 2nd quarter. Canada Pension Plan Investment Board now owns 565,240 shares of the company’s stock worth $6,314,000 after purchasing an additional 273,024 shares during the last quarter. Sivik Global Healthcare LLC acquired a new stake in shares of Endo International PLC during the 2nd quarter worth about $2,793,000. River & Mercantile Asset Management LLP boosted its stake in shares of Endo International PLC by 116.3% during the 3rd quarter. River & Mercantile Asset Management LLP now owns 358,540 shares of the company’s stock worth $3,071,000 after purchasing an additional 192,790 shares during the last quarter. Finally, Van ECK Associates Corp boosted its stake in shares of Endo International PLC by 67.1% during the 3rd quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock worth $2,921,000 after purchasing an additional 136,873 shares during the last quarter. 90.32% of the stock is currently owned by institutional investors.
The stock has a market cap of $1,359.98, a P/E ratio of 1.26 and a beta of 0.53. The company has a debt-to-equity ratio of 10.20, a current ratio of 1.02 and a quick ratio of 0.80.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last released its quarterly earnings results on Thursday, November 9th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.85 by $0.06. Endo International PLC had a negative net margin of 126.97% and a positive return on equity of 56.97%. The company had revenue of $786.90 million for the quarter, compared to analysts’ expectations of $794.93 million. During the same period last year, the company earned $1.01 EPS. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. equities research analysts forecast that Endo International PLC will post 3.54 EPS for the current fiscal year.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.